| Literature DB >> 30347198 |
Veera Kainulainen1, Sonja Elf2, Petri Susi3, Minna Mäki2, Anne Pitkäranta4, Janne O Koskinen5, Riitta Korpela1, Kevin E Eboigbodin6.
Abstract
BACKGROUND: Rhinovirus (RV), a major cause of respiratory infection in humans, imposes an enormous economic burden due to the direct and indirect costs associated with the illness. Accurate and timely diagnosis is crucial for deciding the appropriate clinical approach and minimizing unnecessary prescription of antibiotics. Diagnosis of RV is extremely challenging due to genetic and serological variability among its numerous types and their similarity to enteroviruses.Entities:
Keywords: Amplification; Diagnostics; Isothermal; Point-of-care; RT-SIBA; Rhinovirus; Virus
Mesh:
Substances:
Year: 2018 PMID: 30347198 PMCID: PMC7113843 DOI: 10.1016/j.jviromet.2018.10.015
Source DB: PubMed Journal: J Virol Methods ISSN: 0166-0934 Impact factor: 2.014
Fig. 1Rhinovirus amplification by reverse-transcription strand invasion–based amplification (RT-SIBA). 1) Rhinovirus RNA is reverse transcribed to cDNA by the reverse transcriptase enzyme 2) SIBA amplification requires an invasion oligonucleotide (IO) and two target-specific primers. 3) Single strand binding protein, Gp32 binds to oligonucleotides in order to reduce the formation of secondary structures. The recombinase protein, UvsX, coats the IO displacing the bound Gp32. 4) The recombinase-IO complex invades and separates the target duplex. 5) This allows target-specific primers to bind and extend the target via the action of a DNA polymerase. 6) This leads to the synthesis of two copies of the target duplex. 7) The continuous recombinase-mediated target duplex separation and DNA polymerase extension process leads to an exponential amplification under isothermal conditions.
Oligonucleotides used for RV SIBA assay.
| Name | Sequence 5'→3' |
|---|---|
| RV-A F-primer | TGCACTAGCTGCAGGGTTA |
| RV-A R-primer | GTGTGCTCACTTTGAG |
| RV-B F-primer | GTCTCAAGGCTCCAGGGTTT |
| RV-B R-primer | GTGTGCTTAATTCTGAG |
| RV-A IO | CCCCCCCCCCCCCCCAGGGTTAAGGTTAGCCACATTCAGGGGmCmCmGmGmAmGmGmAmCmUmCmA |
| RV-B IO | CCCCCCCCCCCCCCCAGGGTTTAGGTTAGCCGCATTCAGGGGmCmCmGmGmAmGmGmAmCmUmCmA |
For invasion oligonucleotide (IO), bold sequences denote non-homologous seeding regions. mA, mC, mG, and mU denote 2′-O-methyl RNA nucleotides. F, forward; R, reverse; RV, human Rhinovirus; SIBA, strand invasion–based amplification; RV-A assay is designed to detect the sequence between position 421 and 483 within the genome of the human rhinovirus 60 strain ATCC VR-1473 (GenBank: FJ445133.1); RV-B assay is designed to detect the sequence between position 429 and 493 within the genome of the human rhinovirus 17 (GenBank: AF542419.1).
Fig. 2Optimization of RV SIBA reaction conditions using different invasion oligonucleotide (IO) concentrations. (A) Amplification of 1000 copies of rhinovirus A60 RNA. (B) amplification of 1000 copies of rhinovirus B17 RNA; RV-A-IO, rhinovirus A invasion oligonucleotide; RV-B-IO, rhinovirus B invasion oligonucleotide.
Fig. 3Sensitivity of RV SIBA assay for detection of rhinoviruses (RVs). (A) rhinovirus A60 RNA. (B) rhinovirus B17 RNA; NTC, no template control.
Analytical sensitivity and average detection time of RT-SIBA vs. RT-PCR for the detection of RV.
| RNA copy number/ reaction | RT-SIBA | RT-PCR | ||
|---|---|---|---|---|
| Average amount of time taken to achieve positive results (min) | Average cycle threshold to achieve positive results (Ct) | |||
| RV-A | RV-B | RV-A | RV-B | |
| 105 | 20 | 20 | 25 | 22 |
| 104 | 23 | 24 | 29 | 26 |
| 103 | 25 | 28 | 34 | 29 |
| 102 | 28 | 31 | ND | 33 |
| 101 | 40 | 34 | ND | ND |
| 0 | ND | ND | ND | ND |
List of microbes used for cross-reactivity testing.
| Microbial strains | RV SIBA | RV PCR |
|---|---|---|
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – |
Detection of RV clinical isolates using RV RT-SIBA and RT-PCR.
| Microbial strains | RV SIBA | RV PCR |
|---|---|---|
| RV-A1b | + | + |
| RV-A2 | – | + |
| RV-A12 | + | + |
| RV-A16 | + | + |
| RV-A20 | + | + |
| RV-A30 | + | + |
| RV-A34 | + | + |
| RV-A40 | + | + |
| RV-A44 | + | + |
| RV-A58 | + | + |
| RV-A66 | + | + |
| RV-A74 | + | + |
| RV-A78 | + | + |
| RV-A80 | + | + |
| RV-A85 | + | + |
| RV-A90 | + | + |
| RV-A95 | + | + |
| RV-B14 | + | + |
| RV-B26 | + | + |
| RV-B52 | + | + |
| RV-B99 | + | + |
| CV-B3 | – | – |
| CV-B4 | – | – |
| CV-A9 | – | – |
| EV-11 | – | – |
| EV-30 | – | – |
RV, rhinovirus; CV, coronavirus; EV, enterovirus.
Clinical performance of RV SIBA assay vs. RT-PCR assay for detection of RV virus types.
| RV SIBA | RV PCR | |||
|---|---|---|---|---|
| Positive | Negative | Positive | Negative | |
| Positive | 25 | 1 | 26 | 0 |
| Negative | 0 | 24 | 1 | 23 |
| Total no. of samples | 50 | 50 | ||
| Sensitivity (95% CI) | 96% (81–100) | 100% (87–100.0) | ||
| Specificity (95% CI) | 100 % (86–100) | 100 % (86–100) | ||